Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
Bilgin Osmanodja(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Eva Schrezenmeier(Leibniz Association)
Cited by 85
Related Papers
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
|New England Journal of Medicine|2024|151
TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2019|43
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.
|Transplantation|2024|0